Servier, an international pharmaceutical group, has announced its acquisition of Day One Biopharmaceuticals for a total equity value of approximately $2.5 billion. The acquisition is expected to strengthen Servier's position in rare oncology and expand its pipeline with programs targeting adult and pediatric cancers with high unmet needs.
The transaction represents a premium of approximately 68% over the closing price of Day One on March 5, 2026, and a premium of approximately 86% over the one-month volume weighted average price (VWAP) of Day One as of March 5, 2026.
Servier plans to fund the acquisition through existing cash and investments. The completion of the tender offer is subject to customary closing conditions, including the tender by Day One shareholders of at least a majority of the issued and outstanding shares of Day One common stock and the receipt of U.S. antitrust clearance.
In the 2024/25 financial year, Servier achieved revenues of €6.9 billion. Day One Biopharmaceuticals, based in Brisbane, California, is a commercial-stage biopharmaceutical company focused on addressing the lack of therapeutic development in pediatric cancer.
The acquisition is in line with Servier's 2030 ambition to develop innovative treatments for patients with high unmet medical needs, particularly in rare cancers and neurological diseases. This move is expected to accelerate innovation for people living with rare cancer and reinforce Servier's commitment to advancing targeted therapies. The market has reacted to these announcements by moving the company's shares -3.24% to a price of $10.16. For more information, read the company's full 8-K submission here.
